Table 2 Demographic and clinical characteristics according to alpha 1 antitrypsin genotypes
From: Alpha 1 antitrypsin distribution in an allergic asthmatic population sensitized to house dust mites
PI*MM (n = 503) | PI*MS (n = 110) | PI*MZ (n = 15) | PI*SS (n = 14) | PI*SZ (n = 6) | P value | |
|---|---|---|---|---|---|---|
Sex n (%) | 0.525 | |||||
Male | 178 (35) | 35 (32) | 3 (20) | 6 (43) | 1 (17) | |
Female | 325 (65) | 75 (68) | 12 (80) | 8 (57) | 5 (83) | |
Age, years | 0.818 | |||||
Median (IQ25–75) | 28 (20–38) | 31 (23–38) | 30 (24–38) | 32 (20–36) | 20.5 (19–36) | |
Smokers n (%) | 37 (7.4) | 11 (10) | 4 (26.7) | 2 (14.3) | 0 | 0.0882 |
Intermittent asthma n (%) | 191 (38) | 45 (41) | 4 (26.7) | 9 (64.3) | 4 (66.7) | 0.134 |
Mild persistent asthma (%) | 194 (38.6) | 39(35.5) | 6(40) | 5(35.7) | 2(33.3) | 0.981 |
Moderate persistent asthma n (%) | 78 (15.5) | 18 (16.4) | 4 (26.7) | 0 | 0 | 0.303 |
Severe persistent asthma n (%) | 39 (7.8) | 8 (7.3) | 1 (6.7) | 0 | 0 | 0.958 |
Polyposis n (%) | 9 (1.8) | 6 (5.5) | 2 (13.3) | 0 | 0 | 0.104 |
Chronic sinusitis n (%) | 24 (4.8) | 3 (2.7) | 2 (13.3) | 2 (14.3) | 1 (16.7) | 0.0516 |
Atopic dermatitis n (%) | 17 (3.4) | 4 (3.6) | 0 | 1 (7.1) | 1 (16.7) | 0.271 |
Previous pneumonia n (%) | 4 (0.8) | 1 (0.9) | 0 | 0 | 0 | 1 |
> 3infections/year n (%) | 4 (0.8) | 0 | 0 | 0 | 0 | 1 |
Previous treatment: oral glucocorticosteroids n (%) | 10 (2) | 2 (1.8) | 0 | 0 | 0 | 1 |
Previous treatment: immunotherapy n (%) | 38 (7.6) | 10 (9.1) | 0 | 0 | 0 | 0.804 |
Previous treatment: omalizumab n (%) | 1 (0.2) | 0 | 0 | 0 | 0 | 1 |